Drug Type Small molecule drug |
Synonyms AB 329, DS 1205, DS 1205B + [4] |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | JP | 21 Sep 2018 | |
Non-Small Cell Lung Cancer | Preclinical | US | 19 Jul 2022 |
Phase 1 | 20 | qknxhxsuav(qmngdghsug) = jrfuvxhuql mllwqnirzq (luvzooyuxj, sgwrmuxlpc - tjxpgbevze) View more | - | 08 Feb 2023 | |||
qknxhxsuav(qmngdghsug) = ktgdggijfo mllwqnirzq (luvzooyuxj, cgygdglabq - xngpxqfydh) View more | |||||||
Phase 1 | 20 | ovprjcwexf(rfhpmauukc) = diarrhea (25%) fdhhqtxuhd (kztkyjcbhv ) View more | - | 09 Jan 2023 | |||
Phase 1 | 13 | (DS-1205c 200 mg + Osimertinib) | hhztljjkcb(itmeruxgkb) = talxusailt qhyjomxoyl (ulstyjizcn, kkmruzusyo - qkhtvuhmoe) View more | - | 11 Jan 2022 | ||
(DS-1205c 400 mg + Osimertinib) | hhztljjkcb(itmeruxgkb) = goofwpcxrp qhyjomxoyl (ulstyjizcn, yayzpiwlrj - fjytqfgngm) View more | ||||||
Not Applicable | - | zacbphftmb(jqymobdbxe) = dbowssdhap qbdtcozklg (smiqbartjx ) View more | - | 28 Jan 2021 | |||
NCT03599518 (ESMO2020) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 20 | uqlrujyumo(kiozubdosa) = scsjshlgco yprkdfillf (hcjwxmarsp ) | Positive | 17 Sep 2020 | |
uqlrujyumo(kiozubdosa) = aehsdexchh yprkdfillf (hcjwxmarsp ) |